ESG

We are committed to corporate social responsibility initiatives that radiate light and warmth into our society.

Compliance

2025
Q3 2025
September

Held the 26th DAAC (Dong-A Anti-Corruption Committee) meeting

August

Held the 4th, 5th DCPC (Dong-A ST Compliance Committee) meeting

July

Submitted public disclosure materials for the EconomicBenefit Expenditure Report

Q2 2025
June

Held the 3rd DCPC (Dong-A ST Compliance Committee)
meeting of 2025

Conducted ISO 37001 internal auditor competency training

May

Completed ISO 37001 surveillance audit

Held the 25th DAAC (Dong-A Anti-Corruption Committee) meeting

April

Held the 2nd DCPC (Dong-A ST Compliance Committee)
meeting of 2025

Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001

Q1 2025
March

Collected Compliance Pledge forms from all employees
(1,526 participants)

Conducted first-half CP training for the ETC and DH
Business Division (563 participants, 562 completed)

February

Held the 1st DCPC (Dong-A ST Compliance Committee)
meeting of 2025

Held the 24th DAAC (Dong-A Anti-Corruption Committee) meeting

Reported ISO 37001 management review results to the
Board of Directors

January

Held the 2025 Compliance Program Enhancement Declaration Ceremony

Conducted ISO 37001 management review by top management

2024
Q4 2024
December

Received an ‘A’ grade in the CP rating evaluation from
the Korea Fair Trade Commission

Conducted ISO 37001 second-half monitoring

Conducted CP training for new MRs in the ETC Business Division

Held the 6th DCPC (Dong-A Compliance Committee)
meeting of 2024

November

Conducted regular online CP training for all employees
(1,615 participants, 99.9% completion)

Conducted CP awareness survey

October

Conducted second-half CP training for the ETC Business Division, Marketing Division, and Medical Device Division
(576 participants, 100% completion)

Conducted ISO 37001 internal audit (37 teams across all business divisions)

Held the 5th DCPC (Dong-A ST Compliance Committee)
meeting of 2024

Q3 2024
September

Held the 23rd DAAC (Dong-A Anti-Corruption Committee) meeting

August

Held the 4th DCPC (Dong-A ST Compliance Committee)
meeting of 2024

Submitted public disclosure materials for the Economic
Benefit Expenditure Report

Conducted CP training for employees who violated
compliance regulations during the first half of the year

July

Conducted first-half ISO 37001 monitoring

Q2 2024
June

Held the 3rd DCPC (Dong-A ST Compliance Committee)
meeting of 2024

Held the 22nd DAAC (Dong-A Anti-Corruption Committee) meeting

May

Completed ISO 37001 certification renewal

Held the 21st DAAC (Dong-A Anti-Corruption Committee) meeting

April

Applied for the 2024 CP Rating Evaluation (Korea Fair Trade Mediation Agency)

Held the 2nd DCPC (Dong-A ST Compliance Committee)
meeting of 2024

Conducted CP training for executives with an invited external lecturer

Q1 2024
March

Collected Compliance Pledge forms from all employees
(1,580 participants)

Conducted first-half CP training for the ETC Business Division, Marketing Division, and Medical Device Division
(580 participants, 100% completion)

February

Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001

Reported ISO 37001 management review results to the
Board of Directors

Held the 1st DCPC (Dong-A ST Compliance Committee)
meeting of 2024

January

Conducted ISO 37001 management review by top management

Held the 2024 Compliance Program Declaration Ceremony

2023
Q4 2023
December

Conducted ISO 37001 second-half monitoring

November

Conducted ISO 37001 internal audit covering all business divisions (41 teams audited)

Conducted regular online ISO 37001/ESG training for all employees (1,625 participants, 100% completion)

Conducted employee awareness survey on sustainable management (600 respondents out of 1,625 employees)

Hosted the 1st Dong-A ST Supply Chain Partners Day
(19 Tier-1 partner companies participated)

Conducted second-half CP training for the ETC Business
Division and the Medical Device Division
(120 participants, 100% completion)

October

Conducted second-half CP training for the ETC Business Division

Q3 2023
September

Conducted second-half CP training for the ETC Business Division (400 participants, 100% completion)

August

Conducted online ISO 37001 training for managers
(223 participants, 100% completion)

Conducted CP training for Dong-A Chammed (Ethics Code and Medical Device Fair Competition Code of Conduct)

July

Conducted first-half ISO 37001 monitoring

Held the 20th DAAC (Dong-A Anti-Corruption Committee) meeting

Q2 2023
June

Respond to the Economic Benefit Expenditure Report survey (submitted 2022 expenditure report data)

Conducted CP monitoring on ETC Distribution Policy

May

Conducted CP monitoring on the Wholesale Sales Policy of the Distribution Management Department

Conducted CP training for Dong-A Chammed (affiliate company)

Conducted CP monitoring for the Medical Device Division

April

Conducted CP monitoring for a affiliated companies

Conducted first-half CP training for the ETC Business
Division and the Medical Device Division
(520 participants, 100% completion)

Q1 2023
February

Collected Compliance Pledge forms from all employees
(1,621 participants, 100% completion)

Reported ISO 37001 management review results to the
Board of Directors

Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001

January

Conducted ISO 37001 management review by top management

Conducted CP training for new MRs in the ETC Business Division

2022
Q4 2022
December

Conducted ISO 37001 second-half monitoring

Provided CP training for the Marketing Division (51 participants)

November

Conducted online CP/ESG training for all employees
(1,593 participants, 100% completion)

October

Conducted second-half CP training for the ETC Business Division
(317 participants)

Q3 2022
September

Conducted CP refresher training for new MRs in the ETC Sales Division (20 participants)

August

Conducted CP training for newly hired employee in the ETC Division (11 participants)

Conducted CP training for new PMs in the Marketing Division
(3 participants)

Q2 2022
May

Conducted first-half CP training for the Medical Device and Diagnostic Divisions (54 participants)

April

Conducted first-half CP training for the ETC Business
Division (480 sales representatives)

Q1 2022
March

Conducted CP training for new PMs in the Marketing Division
(5 participants)

January

Conducted Business Partner CP training for the medical
Device Division (50 participants)

Compliance Operating System
Risk Assessment

Dong-A ST conducts an annual risk assessment for relevant department to ensure that rebate practices, which could undermine the company’s business foundation, do not occur.

We also conduct continuous risk management and assess its effectiveness based on the results of the risk assessment

  • Risk Identification
    Identifying compliance risks by analyzing relevant regulations and operational content
    (Identifying risks, categorizing risk types, managing risks by type, monitoring teams with risks)
  • Risk Assessment
    Evaluating the likelihood and impact of identified compliance risks
  • Risk Mitigation Plan
    Developing comprehensive plans to manage identified risks
    (including assigning risk owners, establishing response strategies, and designing control measures)
  • Follow-Up
    Strengthening control measures and implementing improvement activities in risk-vulnerable areas
    (updating risk items, supplementing guidelines, and offering continuous training and follow-up actions)
Anti-Bribery Policy
Dong-A ST, based on the founding spirit of 'Jeongdo, Sincerity, and Consideration' and the philosophy of 'Jeongdo Management', declares the following anti-bribery policy to fulfill its social responsibilities and establish a fair and transparent corporate culture.
  • 1

    The company and its employees will strictly comply with all domestic and international
    anti-corruption laws and internal regulations, prohibiting all forms of corruption.

  • 2

    We will establish and continuously improve systems related to anti-corruption to meet our objectives.

  • 3

    Employees are encouraged to promptly report any corruption, and the company will ensure
    that whistleblowers are fully protected from retaliation.

  • 4

    The anti-bribery officer will be granted the authority and independence needed to oversee anti-bribery efforts.

  • 5

    A zero-tolerance policy will be enforced for employee corruption,
    with strict penalties applied according to company regulations.

  • 6

    We will ensure that our anti-bribery policy is effectively communicated to all relevant business stakeholders.

President of Dong-A ST
Jae-hoon Jeong
Anti-Corruption Management System
Holdings Company
Healthcare
Biopesticide
F/B
Logistics
Packaging
Engineering
IT
Plant
Global